Sign in

Private company

Rubius Therapeutics (United States)

Logo: rubiustx.com4

American biological products company based in Cambridge, founded in 20131

In its 2023 annual report the company says: “We are a biopharmaceutical company that has developed a platform and pipeline focused on creating an entirely new class of cellular medicines called Red Cell Therapeutics, or RCTs, for the treatment of cancer and autoimmune diseases.”54

Last updated Oct 21, 2026.

Overview

2013Founded1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersCambridge, United States1
  • Websitewww.rubiustx.com
  • Legal formDelaware corporation1
  • Incorporated inDE5
  • Business addressC/O Verdolino & Lowey, P.C., 124 Washington Street, Suite 101, Foxboro, Ma 020355
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • LEI549300ER84PB0QV6HZ763
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States3
  • Registered withDivision of Corporations, Department of State, 53256883

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-1187.4%Return on equity6
0.00×Debt to equity6
-$155.4MFree cash flow6

Financial statements

Revenue6$0 in 2022
02020: $0$020202021: $0$020212022: $0$02022
Operating income789106-$178.4M in 2022+1544% since 2016
-$200.0M-$150.0M-$100.0M-$50.0M02016: -$10.9M-$10.9M20162017: -$43.3M-$43.3M2017+299%2018: -$91.7M-$91.7M2018+112%2019: -$169.6M-$169.6M2019+85%2020: -$166.4M-$166.4M2020−2%2021: -$194.6M-$194.6M2021+17%2022: -$178.4M-$178.4M2022−8%
Net income789106-$179.7M in 2022+1531% since 2016
-$200.0M-$150.0M-$100.0M-$50.0M02016: -$11.0M-$11.0M20162017: -$43.8M-$43.8M2017+298%2018: -$89.2M-$89.2M2018+103%2019: -$163.5M-$163.5M2019+83%2020: -$167.7M-$167.7M2020+3%2021: -$196.5M-$196.5M2021+17%2022: -$179.7M-$179.7M2022−9%
Fiscal year2016201720182019202020212022
Revenue$06$06$06
Research and development$8.4M7$21.2M8$51.8M9$112.4M10$116.1M6$141.6M6$96.4M6
Operating expenses$194.6M6$178.4M6
Operating income-$10.9M7-$43.3M8-$91.7M9-$169.6M10-$166.4M6-$194.6M6-$178.4M6
Interest$149.0K7$309.0K8$464.0K9$2.6M10$4.2M6$6.4M6$3.9M6
Net income-$11.0M7-$43.8M8-$89.2M9-$163.5M10-$167.7M6-$196.5M6-$179.7M6
Earnings per share-$2.086-$2.236-$1.996
Earnings per share (diluted)-$2.086-$2.236-$1.996
Shares (weighted, basic)88.0M shares690.3M shares6
Shares (weighted, diluted)88.0M shares690.3M shares6

Compare Rubius Therapeutics (United States) with another company

Corporate structure

Rubius Therapeutics (United States) sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Rubius Therapeutics (United States)

  • Rubius Therapeutics (United States) Cambridge, Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Rubius Therapeutics (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$570.0K6 Dec 31, 2022$69.4M6 Dec 31, 2021−99.2%
Accumulated depreciation$424.0K6 Dec 31, 2022$17.9M6 Dec 31, 2021−97.6%
Property and equipment, net$146.0K6 Dec 31, 2022$51.5M6 Dec 31, 2021−99.7%
Operating-lease assets (leased space)$2.7M6 Dec 31, 2022$35.1M6 Dec 31, 2021−92.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$14.9M6 Dec 31, 2022$225.8M6 Dec 31, 2021−93.4%
Marketable securities, current$06 Dec 31, 2022$010 Dec 31, 2021

Leadership

Who has led Rubius Therapeutics (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Pablo J. Cagnoni2018–2022
  2. Dannielle Appelhans2023

President

  1. Torben Straight Nissen2018–2019
  2. Pablo J. Cagnoni2020–2022
  3. Dannielle Appelhans2023

Chief financial officer

  1. Andrew M. Oh2018–2020
  2. Jose Carmona2020–2022

Chief operating officer

  1. Dannielle Appelhans2021–2022
201520202025
Board members and other officers (14)

Timeline

  1. Apr 6, 20238-K Executive or director change; Shareholder vote33
  2. Mar 3, 20238-K Listing notice or transfer; Executive or director change34
  3. Feb 22, 20238-K Other events35
  4. Feb 6, 20238-K Listing notice or transfer; Executive or director change36
  5. Feb 1, 2023New chief executive Dannielle Appelhans becomes CEO13
  6. Dec 21, 20228-K Completed an acquisition or sale37
  7. Dec 14, 20228-K Ended a material agreement38
  8. Dec 12, 20228-K Entered a material agreement39
  9. Nov 2, 20228-K Exit or restructuring costs; Executive or director change40
  10. Oct 17, 20228-K Executive or director change41
  11. Oct 13, 20228-K Debt or obligation accelerated42
  12. Sep 13, 20228-K Exit or restructuring costs; Other events43
  13. Aug 12, 20228-K Listing notice or transfer; Executive or director change44
  14. Jul 17, 2018New chief executive Pablo J. Cagnoni becomes CEO14
  15. 2013Founded Founded1

Calendar

When it reported results

  1. Aug 9, 2022Reported quarterly or annual results45
  2. May 10, 2022Reported quarterly or annual results46
  3. Feb 25, 2022Reported quarterly or annual results47
  4. Nov 8, 2021Reported quarterly or annual results48

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

80 filings to the SEC since October 2021: 2 annual reports, 4 quarterly reports, 22 major events, 23 insider forms, 9 large holders, 20 other. The latest 20:

  1. Apr 10, 202315-12G EDGAR
  2. Apr 10, 2023SC 13G/A EDGAR
  3. Apr 6, 20238-K EDGAR
  4. Mar 28, 202325 EDGAR
  5. Mar 9, 2023DEF 14A EDGAR
  6. Mar 3, 20238-K EDGAR
  7. Mar 3, 2023SC 13G/A EDGAR
  8. Mar 2, 2023PRER14A EDGAR
  9. Feb 27, 202310-K EDGAR
  10. Feb 27, 20234 OWNERSHIP DOCUMENT EDGAR
  11. Feb 27, 2023PRE 14A EDGAR
  12. Feb 27, 2023S-8 POS EDGAR
  13. Feb 27, 2023S-8 POS EDGAR
  14. Feb 27, 2023S-8 POS EDGAR
  15. Feb 27, 2023S-8 POS EDGAR
  16. Feb 27, 2023S-8 POS EDGAR
  17. Feb 22, 2023RW EDGAR
  18. Feb 22, 20238-K EDGAR
  19. Feb 14, 2023SC 13G/A EDGAR
  20. Feb 9, 2023SC 13G/A EDGAR

The 80 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

10 open-market trades by officers, directors and large owners since October 2021: 1 buys and 9 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 24, 2023Appelhans DannielleCEO and PresidentSale10,385$0.13$1.4KForm 4
Feb 1, 2023CAGNONI PABLO JDirectorSale8,448$0.25$2.1KForm 4
Feb 1, 2023Appelhans DannielleCEO and PresidentSale3,878$0.25$970Form 4
Jan 31, 2023CAGNONI PABLO JDirectorSale7,240$0.24$1.7KForm 4
Jan 31, 2023Turka Laurence A.Chief Scientific OfficerSale2,593$0.24$622Form 4
Aug 10, 2022Appelhans DannielleCEO and PresidentSale5,737$0.80$4.6KForm 4
Apr 21, 2022Epstein David RDirectorBuy30,000$1.44$43.2KForm 4
Feb 1, 2022CAGNONI PABLO JDirectorSale6,730$6.57$44.2KForm 4
Feb 1, 2022Keson-Brookes MaikenCLO & Corp. SecretarySale2,732$6.57$17.9KForm 4
Feb 1, 2022Turka Laurence A.Chief Scientific OfficerSale2,517$6.57$16.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Rubius Therapeutics (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARRubius Therapeutics, Inc.2
  • CIK0001709401
  • Employer ID (EIN)04-26881092
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • Business addressC/O Verdolino & Lowey, P.C., 124 Washington Street, Suite 101, Foxboro, MA 020352
  • Phone617-679-96002
  • Shares outstanding90,397,732 as of Jan 31, 20236
  • Public float$28.4M as of Jun 30, 20226
  • On EDGAR sinceJun 22, 20172
  • Filings279 in all: 4 (96), 8-K (57), 3 (20), SC 13G/A (17), 10-Q (14), CORRESP (6), DEF 14A (6), 10-K (5)2
    All 35 form types

    S-8 (5), S-8 POS (5), SC 13G (5), 10-Q/A (4), DEFA14A (4), UPLOAD (4), EFFECT (3), 424B5 (2), 5 (2), D (2), DRS/A (2), DRSLTR (2), PRE 14A (2), S-1/A (2), S-3 (2), 10-K/A (1), 15-12G (1), 25 (1), 424B4 (1), 8-A12B (1), CERT (1), CT ORDER (1), DRS (1), PRER14A (1), RW (1), S-1 (1), S-1MEF (1)

  • Latest filingsAnnual report (10-K) Feb 27, 2023
    Quarterly report (10-Q) Nov 9, 2022
    Proxy statement (DEF 14A) Mar 9, 2023
    Latest 8-K (8-K) Apr 6, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54